Abbott Laboratories

NYSE: ABT · Real-Time Price · USD
131.34
2.06 (1.59%)
At close: Aug 15, 2025, 10:14 AM

Abbott Laboratories Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
43.11B 42.34B 41.95B 41.22B 40.73B 40.33B 40.11B 39.96B 40.23B 41.51B 43.65B 45.03B 45.55B 44.51B 43.08B 42.31B 40.23B 37.34B
Cost of Revenue
20.3B 20.57B 20.6B 20.21B 20.11B 20.07B 20.07B 20.2B 20.3B 20.75B 21.33B 21.47B 21.14B 20.5B 19.86B 19.62B 19.27B 18.27B
Gross Profit
22.81B 21.77B 21.35B 21.01B 20.62B 20.26B 20.04B 19.75B 19.93B 20.76B 22.32B 23.56B 24.41B 24.01B 23.21B 22.69B 20.96B 19.07B
Operating Income
7.59B 7.18B 6.88B 6.75B 6.61B 6.44B 6.45B 6.03B 6.05B 6.88B 8.36B 9.37B 10.29B 9.95B 9.2B 9.17B 8B 6.64B
Interest Income
264M 346M 344M 342M 348M 364M 385M 384M 342M 270M 183M 106M 61M 46M 43M 41M 41M 39M
Pretax Income
7.9B 7.36B 7.01B 6.78B 6.51B 6.54B 6.66B 6.19B 6.28B 6.99B 8.31B 9.31B 10.05B 9.04B 8.21B 8.27B 7.2B 6.38B
Net Income
13.98B 13.5B 13.4B 5.77B 5.56B 5.63B 5.72B 5.16B 5.16B 5.8B 6.93B 7.89B 8.55B 7.72B 7.07B 7.24B 6.38B 5.72B
Selling & General & Admin
11.92B 11.75B 11.65B 11.47B 11.28B 11.08B 10.87B 11.01B 11.04B 11.07B 11.11B 11.27B 11.31B 11.28B 11.28B 10.85B 10.38B 9.93B
Research & Development
2.88B 2.84B 2.82B 2.78B 2.73B 2.74B 2.71B 2.72B 2.83B 2.81B 2.85B 2.92B 2.81B 2.78B 2.74B 2.68B 2.59B 2.5B
Other Expenses
420M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
15.22B 14.59B 14.47B 14.26B 14.01B 13.82B 13.59B 13.72B 13.88B 13.88B 13.96B 14.19B 14.13B 14.06B 14.01B 13.53B 12.96B 12.43B
Interest Expense
502M 620M 603M 686M 668M 653M 698M 627M 535M 467M 315M 240M 303M 354M 410M 435M 442M 467M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 22M 22M 22M
Cost & Expenses
35.51B 35.16B 35.07B 34.46B 34.11B 33.89B 33.66B 33.93B 34.17B 34.63B 35.29B 35.66B 35.26B 34.56B 33.88B 33.14B 32.23B 30.69B
Income Tax Expense
-6.08B -6.15B -6.39B 1.01B 952M 908M 941M 1.03B 1.11B 1.19B 1.37B 1.42B 1.49B 1.32B 1.14B 1.03B 828M 658M
Shares Outstanding (Basic)
1.74B 1.75B 1.73B 1.73B 1.73B 1.73B 1.73B 1.74B 1.74B 1.74B 1.74B 1.74B 1.75B 1.75B 1.76B 1.77B 1.77B 1.78B
Shares Outstanding (Diluted)
1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.76B 1.76B 1.77B 1.78B 1.79B 1.79B 1.79B
EPS (Basic)
8.06 7.79 7.74 3.33 3.21 3.25 3.30 2.97 2.96 3.32 3.96 4.50 4.87 4.39 4.00 4.09 3.60 3.23
EPS (Diluted)
7.99 7.71 7.65 3.29 3.17 3.21 3.26 2.94 2.93 3.29 3.92 4.45 4.81 4.33 3.95 4.04 3.56 3.20
EBITDA
10.76B 11.14B 10.83B 10.69B 10.42B 10.43B 10.61B 10.05B 10.04B 10.71B 11.89B 12.9B 13.73B 12.82B 12.16B 12.23B 11.12B 10.28B
EBIT
8.4B 7.97B 7.62B 7.46B 7.18B 7.19B 7.36B 6.82B 6.81B 7.46B 8.62B 9.55B 10.35B 9.4B 8.62B 8.71B 7.64B 6.84B
Depreciation & Amortization
2.36B 3.17B 3.22B 3.22B 3.25B 3.24B 3.24B 3.24B 3.23B 3.25B 3.27B 3.34B 3.38B 3.43B 3.54B 3.52B 3.48B 3.43B